Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relap… Read more
Rigel Pharmaceuticals Inc (RIGL) - Total Assets
Latest total assets as of December 2025: $513.59 Million USD
Based on the latest financial reports, Rigel Pharmaceuticals Inc (RIGL) holds total assets worth $513.59 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Rigel Pharmaceuticals Inc - Total Assets Trend (1999–2025)
This chart illustrates how Rigel Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Rigel Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Rigel Pharmaceuticals Inc's total assets of $513.59 Million consist of 46.8% current assets and 53.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.9% |
| Accounts Receivable | $51.76 Million | 10.1% |
| Inventory | $11.51 Million | 2.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $24.75 Million | 4.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1999–2025)
This chart illustrates how Rigel Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rigel Pharmaceuticals Inc's current assets represent 46.8% of total assets in 2025, a decrease from 49.7% in 1999.
- Cash Position: Cash and equivalents constituted 7.9% of total assets in 2025, down from 34.0% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 10.1% of total assets.
Rigel Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Rigel Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Rigel Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Rigel Pharmaceuticals Inc generates 0.57x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Rigel Pharmaceuticals Inc generates $ 71.46 in net profit.
Rigel Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.42 | 2.13 | 3.78 |
| Quick Ratio | 2.30 | 2.04 | 3.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $140.93 Million | $ 71.80 Million | $ 144.74 Million |
Rigel Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Rigel Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.32 |
| Latest Market Cap to Assets Ratio | 0.90 |
| Asset Growth Rate (YoY) | 213.2% |
| Total Assets | $513.59 Million |
| Market Capitalization | $462.46 Million USD |
Valuation Analysis
Near Book Valuation: The market values Rigel Pharmaceuticals Inc's assets close to their book value ( 0.90x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Rigel Pharmaceuticals Inc's assets grew by 213.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Rigel Pharmaceuticals Inc (1999–2025)
The table below shows the annual total assets of Rigel Pharmaceuticals Inc from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $513.59 Million | +213.21% |
| 2024-12-31 | $163.98 Million | +39.88% |
| 2023-12-31 | $117.22 Million | -12.70% |
| 2022-12-31 | $134.28 Million | -19.75% |
| 2021-12-31 | $167.33 Million | +51.60% |
| 2020-12-31 | $110.38 Million | -25.20% |
| 2019-12-31 | $147.57 Million | +6.08% |
| 2018-12-31 | $139.11 Million | +16.79% |
| 2017-12-31 | $119.11 Million | +52.44% |
| 2016-12-31 | $78.13 Million | -40.69% |
| 2015-12-31 | $131.75 Million | -14.52% |
| 2014-12-31 | $154.13 Million | -31.82% |
| 2013-12-31 | $226.06 Million | -27.09% |
| 2012-12-31 | $310.04 Million | +20.59% |
| 2011-12-31 | $257.11 Million | +37.71% |
| 2010-12-31 | $186.69 Million | +32.65% |
| 2009-12-31 | $140.74 Million | -2.16% |
| 2008-12-31 | $143.86 Million | +24.24% |
| 2007-12-31 | $115.79 Million | +2.25% |
| 2006-12-31 | $113.24 Million | -23.31% |
| 2005-12-31 | $147.67 Million | +87.34% |
| 2004-12-31 | $78.82 Million | +41.96% |
| 2003-12-31 | $55.52 Million | +25.22% |
| 2002-12-31 | $44.34 Million | -4.53% |
| 2001-12-31 | $46.45 Million | -27.72% |
| 2000-12-31 | $64.26 Million | +274.29% |
| 1999-12-31 | $17.17 Million | -- |